secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phathom Pharmaceuticals, Inc. (PHAT)
CIK:        0001783183
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001193125-23-152946
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phathom prices public offering of 11.125M shares at $11.75/share for ~$130.7M gross
--------------------------------------------------------------------------------

- Offering of 11,125,000 shares at $11.75/share; gross proceeds ~$130.7M.
- Underwriters have 30-day option to purchase up to 1,668,750 additional shares.
- Net proceeds ~$122.4M ($140.8M if option exercised) to fund vonoprazan clinical dev., pre-commercial, and working capital.
- Offering expected to close May 26, 2023; Jefferies and Evercore ISI act as joint bookrunners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523152946/0001193125-23-152946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783183/000119312523152946/d452618d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-152946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer